Retatrutide Injection Frequency: What Research Shows

Retatrutide's injection frequency is not a matter of personal preference in the published research — it is the schedule its Phase 2 human trial actually used. This reference explains what that trial reported, why a long-acting triple-receptor peptide is generally studied on a weekly rather than daily interval, and how frequency interacts with the reconstitution arithmetic that determines how many doses a single vial supplies. It is written for research and educational purposes only and is not medical advice.

What the Phase 2 trial used

The main published human data on retatrutide comes from a Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023). Participants received subcutaneous retatrutide once weekly, at one of several target doses tested against placebo. That is Phase 2, human-trial evidence — one step below the larger, confirmatory Phase 3 trials that typically precede FDA approval. Retatrutide currently has no approved pharmaceutical formulation, so this trial is the only source that documents a verified retatrutide injection frequency; any figure discussed here describes what was tested in that trial, not a personal recommendation.

Independent research protocols that reference retatrutide are not bound to the trial's design, but the ones that specify a frequency generally converge on the same once-weekly pattern. That convergence has a pharmacological reason behind it, covered next, rather than being a simple copy of the trial.

Why weekly, not daily

Retatrutide is a triple agonist, acting on GLP-1, GIP, and glucagon receptors at once — a design shared conceptually with other long-acting metabolic peptides such as semaglutide and tirzepatide, both of which are also studied and approved on weekly schedules. See the semaglutide vs tirzepatide vs retatrutide comparison for how the three line up on mechanism and research maturity. Peptides in this class are built to persist in circulation for an extended period, which is what allows a single injection to sustain an effect across a full week rather than fading well before the next dose.

That's a different clearance profile from faster-acting peptide classes, such as GHRH analogs, which clear quickly enough that research protocols and approved labels for those compounds generally call for daily dosing instead. Frequency follows from how long a compound stays active after injection — it isn't an independent design choice, and comparing a weekly schedule to a daily one across different peptide classes isn't a fair comparison, because the two are answering to entirely different clearance timelines.

Frequency and the reconstitution math

Frequency and reconstitution math answer two different questions. Frequency tells you how many times per week you draw from the vial. Reconstitution math tells you the concentration of what's in the vial, and from that, the volume and syringe units for any single draw. Combined, the two answer a third question: how many weeks will one vial last.

Concentration is set once, at the moment bacteriostatic water is added:

Concentration = vial mass (mg) ÷ water added (mL)

A commonly cited reference point for retatrutide scales water to vial size at 1 mL per 10 mg, holding concentration at 10 mg/mL across the common 10 mg, 15 mg, 20 mg, and 30 mg vial sizes. That concentration doesn't change based on how often the vial is drawn from — only the running total of mg withdrawn changes, week to week.

Worked example: vial life at a weekly frequency

Setup. A 30 mg retatrutide vial reconstituted with 3 mL of bacteriostatic water.

Step 1 — concentration. 30 mg ÷ 3 mL = 10 mg/mL.

Step 2 — volume per dose. At a 4 mg target dose, volume = 4 mg ÷ 10 mg/mL = 0.4 mL.

Step 3 — syringe units. On a U-100 insulin syringe, 1 mL = 100 units, so 0.4 mL × 100 = 40 units per injection.

Step 4 — vial life at a once-weekly frequency. The 30 mg vial holds 30 ÷ 4 = 7.5 full doses. At one injection per week, that vial supplies 7.5 weeks — a little over 52 days — before a new vial is needed.

Change any one input and the vial-life number changes with it. A 20 mg vial at the same 10 mg/mL concentration holds 20 ÷ 4 = 5 doses — 5 weeks at a weekly frequency. A lower weekly dose, such as 2 mg from that same 30 mg vial (0.2 mL, or 20 units), stretches the vial to 15 doses — 15 weeks. Dose size and frequency both draw down the same fixed pool of total mg in the vial; neither one changes the concentration itself. For the full doses-per-vial breakdown across all four common sizes, see the retatrutide vial size guide.

Keeping frequency and concentration in sync

A weekly schedule only stays accurate if the concentration behind it hasn't drifted between draws. Track the date a vial was reconstituted, not just the date it was opened — a reconstituted solution is far less stable than the lyophilized powder it started as, even stored refrigerated. Logging each weekly draw against the vial-life estimate above also catches arithmetic errors early: if a vial expected to hold 7.5 doses runs dry at week 5, the concentration used in the original calculation was likely off, not the compound itself.

Research protocols vs. the trial schedule

Some published research protocols pair retatrutide's weekly frequency with a dose titration schedule, stepping the target dose up over a series of weekly injections rather than holding one fixed amount throughout. The retatrutide dosage titration schedule guide covers that stepped approach and its own reconstitution math in detail. Frequency and titration are separate variables — a schedule can hold weekly frequency constant while the dose itself changes step to step, and the vial-life math above applies at whatever dose is current for that step.

Common mistakes

• Treating "once weekly" as flexible. Spacing injections unevenly doesn't reproduce a weekly schedule's effect, since the trial data behind it reflects a consistent interval, not an approximate one.
• Confusing dose size with frequency. A larger single injection does not substitute for a skipped week; they answer different questions in the math above.
• Reusing a vial-life estimate after changing concentration. The 7.5-week estimate above only holds at 10 mg/mL and a 4 mg weekly dose. Changing the water volume or the dose changes every downstream number.
• Assuming a daily schedule from another peptide class transfers to retatrutide. Faster-clearing compounds and long-acting triple agonists like retatrutide are not interchangeable on frequency; check the specific compound's trial data rather than pattern-matching from a different peptide's schedule.

Use the calculator

Enter your retatrutide vial size, bacteriostatic water volume, and target dose into the peptide dosage calculator to get exact syringe units, then use that output alongside your intended frequency to work out how long a vial will last. For the full reconstitution walkthrough, see the retatrutide dosage calculator guide.